Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Enliven Therapeutics ( (ELVN) ) is now available.
On June 13, 2025, Enliven Therapeutics announced an underwriting agreement for a public offering of 9,920,987 shares of common stock and pre-funded warrants, expected to raise approximately $216.1 million in net proceeds. This strategic move is anticipated to bolster Enliven’s financial position, potentially enhancing its market presence in the biopharmaceutical industry, with the offering set to close on June 16, 2025, subject to customary conditions.
The most recent analyst rating on (ELVN) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Enliven Therapeutics stock, see the ELVN Stock Forecast page.
Spark’s Take on ELVN Stock
According to Spark, TipRanks’ AI Analyst, ELVN is a Underperform.
Enliven Therapeutics’ stock is challenged by its early-stage financial profile with no revenue and ongoing losses. Despite strong liquidity, the reliance on external financing and lack of profitability weigh heavily. Technical indicators reinforce a cautious approach, as the stock shows bearish trends. Valuation metrics further reflect the typical risk profile of a biotech company in development.
To see Spark’s full report on ELVN stock, click here.
More about Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, focused on the discovery and development of small molecule therapeutics. The company aims to address unmet needs in precision oncology, improving survival and enhancing well-being through potentially first-in-class or best-in-class therapies.
Average Trading Volume: 398,850
Technical Sentiment Signal: Buy
Current Market Cap: $1.08B
See more insights into ELVN stock on TipRanks’ Stock Analysis page.